Multiple Myeloma in Relapse
90
25
36
17
Key Insights
Highlights
Success Rate
71% trial completion
Published Results
11 trials with published results (12%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
7.8%
7 terminated out of 90 trials
70.8%
-15.7% vs benchmark
4%
4 trials in Phase 3/4
65%
11 of 17 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 17 completed trials
Clinical Trials (90)
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma
Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
CAR-T in Relapsed/Refractory Multiple Myeloma
Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma
A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Self-administered Subcutaneous Daratumumab in Patients With Multiple Myeloma
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes
Study to Evaluate the Safety of UF-KURE-BCMA CAR T-Cells in Advanced Myeloma
Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma
UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma
TriPRIL CAR T Cells in Multiple Myeloma
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
Ixazomib + Pomalidomide + Dexamethasone In MM
Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial.
Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma